MALDI mass spectrometry imaging unravels organ and amyloid-type specific peptide signatures in pulmonary and gastrointestinal amyloidosis
- PMID: 34061454
- DOI: 10.1002/prca.202000079
MALDI mass spectrometry imaging unravels organ and amyloid-type specific peptide signatures in pulmonary and gastrointestinal amyloidosis
Abstract
Purpose: Amyloidosis is a disease group caused by pathological aggregation and deposition of peptides in diverse tissue sites. Recently, matrix-assisted laser desorption/ionization mass spectrometry imaging coupled with ion mobility separation (MALDI-IMS MSI) was introduced as a novel tool to identify and classify amyloidosis using single sections from formalin-fixed and paraffin-embedded cardiac biopsies. Here, we tested the hypothesis that MALDI-IMS MSI can be applied to lung and gastrointestinal specimens.
Experimental design: Forty six lung and 65 gastrointestinal biopsy and resection specimens with different types of amyloid were subjected to MALDI-IMS MSI. Ninety three specimens included tissue areas without amyloid as internal negative controls. Nine cases without amyloid served as additional negative controls.
Results: Utilizing a peptide filter method and 21 known amyloid specific tryptic peptides we confirmed the applicability of a universal peptide signature with a sensitivity of 100% and a specificity of 100% for the detection of amyloid deposits in the lung and gastrointestinal tract. Additionally, the frequencies of individual m/z-values of the 21 tryptic marker peptides showed organ- and tissue-type specific differences.
Conclusions and clinical relevance: MALDI-IMS MSI adds a valuable analytical approach to diagnose and classify amyloid and the detection frequency of individual tryptic peptides is organ-/tissue-type specific.
Keywords: MALDI-IMS MS imaging; amyloidosis; formalin-fixed and paraffin-embedded; ion mobility separation.
© 2021 The Authors. Proteomics - Clinical Applications published by Wiley-VCH GmbH.
References
REFERENCES
-
- Benson, M. D., Buxbaum, J. N., Eisenberg, D. S., Merlini, G., Saraiva, M. J. M., Sekijima, Y., Sipe, J. D., & Westermark, P. (2020). Amyloid nomenclature 2020: Update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid, 27(4), 217-222. https://doi.org/10.1080/13506129.2020.1835263
-
- Chiti, F., & Dobson, C. M. (2017). Protein misfolding, amyloid formation, and human disease: A summary of progress over the last decade. Annual Review of Biochemistry, 86, 27-68. https://doi.org/10.1146/annurev-biochem-061516-045115
-
- Buxbaum, J. N. (2019). Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: The role of randomized controlled trials. Amyloid, 26(2), 55-65. https://doi.org/10.1080/13506129.2019.1575201
-
- Gertz, M. A. (2020). Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. American Journal of Hematology, 95(7), 848-860. https://doi.org/10.1002/ajh.25819
-
- Mahmood, S., Bridoux, F., Venner, C. P., Sachchithanantham, S., Gilbertson, J. A., Rowczenio, D., Wagner, T., Sayed, R., Patel, K., Fontana, M., Whelan, C. J., Lachmann, H. J., Hawkins, P. N., Gillmore, J. D., & Wechalekar, A. D. (2015). Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: A long-term observational study. The Lancet Haematology, 2(6), e241-e250. https://doi.org/10.1016/S2352-3026(15)00068-X
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
